First patient enrolls in MMRF’s Horizon Two clinical trial for newly diagnosed multiple myeloma treatment

Wells Messersmith named director of CU Anschutz Cancer Center

Wells Messersmith was named director of the University of Colorado Anschutz Cancer Center, effective Oct. 1.

October 30, 2026

California’s Prop 38 is an historic approach to funding medical research, immunology
The $8.4B bond makes a long-term investment in a field with life-saving power

Throughout my career as a physician and scientist, I’ve seen ideas once considered impossible become breakthroughs that save lives. They happened because talented scientists had the resources, institutions, and sustained support to pursue ambitious ideas. Most importantly, they knew patients could not afford to wait.

October 23, 2026

Vol.52 No.39

By Arie S. Belldegrun

In Brief

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

A University of Oklahoma physician-researcher recently received $2.9 million in funding from NCI to study whether RedHill Biopharma’s drug opaganib, given after CAR T-cell therapy, can help the immune cells fight cancer more effectively.

October 23, 2026

Vol.52 No.39

Funding Opportunities

International Myeloma Society opens applications for over $3M in 2027 research funding

The International Myeloma Society, in partnership with the Paula and Rodger Riney Foundation, is accepting applications for more than $3 million in research funding through its 2027 Translational Research and Career Development awards. The awards support research to improve the prevention, early detection, diagnosis, and treatment of multiple myeloma and related plasma cell disorders, while developing the next generation of researchers in the field.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

An investigational CAR T therapy can lead to deep and durable responses in people with relapsed/refractory multiple myeloma, according to a phase I clinical trial led by investigators at Mass General Brigham Cancer Institute and the University of Chicago Medicine Comprehensive Cancer Center.

October 23, 2026

Vol.52 No.39

In Brief

Moffitt advances patient avatar technologies through $15M federal research initiative

Moffitt Cancer Center is advancing patient avatar technologies through a $15 million federally funded research initiative in collaboration with the Murtha Cancer Center Research Program at the Uniformed Services University of the Health Sciences in Bethesda, Maryland.

October 16, 2026

Vol.52 No.38

First patient enrolls in MMRF’s Horizon Two clinical trial for newly diagnosed multiple myeloma treatment

YOU MAY BE INTERESTED IN

Wells Messersmith named director of CU Anschutz Cancer Center

California’s Prop 38 is an historic approach to funding medical research, immunology
The $8.4B bond makes a long-term investment in a field with life-saving power

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

International Myeloma Society opens applications for over $3M in 2027 research funding

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

Moffitt advances patient avatar technologies through $15M federal research initiative

Renew today!

Subscriber content

Never miss an issue!

Login

First patient enrolls in MMRF’s Horizon Two clinical trial for newly diagnosed multiple myeloma treatment

YOU MAY BE INTERESTED IN

Wells Messersmith named director of CU Anschutz Cancer Center

California’s Prop 38 is an historic approach to funding medical research, immunologyThe $8.4B bond makes a long-term investment in a field with life-saving power

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

International Myeloma Society opens applications for over $3M in 2027 research funding

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

Moffitt advances patient avatar technologies through $15M federal research initiative

Never miss an issue!

Login

California’s Prop 38 is an historic approach to funding medical research, immunology
The $8.4B bond makes a long-term investment in a field with life-saving power